Thermo Fisher Scientific Inc. $TMO Stock Bought by Quintet Private Bank Europe S.A.

Quintet Private Bank Europe S.A. grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 48.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 88,084 shares of the medical research company’s stock after acquiring an additional 28,629 shares during the period. Thermo Fisher Scientific comprises approximately 2.8% of Quintet Private Bank Europe S.A.’s portfolio, making the stock its 9th largest position. Quintet Private Bank Europe S.A.’s holdings in Thermo Fisher Scientific were worth $59,461,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Polaris Financial Partners purchased a new stake in Thermo Fisher Scientific during the 3rd quarter worth about $32,000. Kilter Group LLC acquired a new position in shares of Thermo Fisher Scientific during the second quarter worth about $25,000. Legacy Wealth Managment LLC ID increased its stake in shares of Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after buying an additional 22 shares during the period. Allied Private Wealth LLC acquired a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $26,000. Finally, MBM Wealth Consultants LLC acquired a new position in Thermo Fisher Scientific during the 1st quarter worth approximately $29,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph Holmes sold 420 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc Casper sold 275 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $77,707,171.25. This represents a 0.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,768 shares of company stock valued at $44,122,820 over the last ninety days. 0.33% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on TMO shares. UBS Group upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and raised their price objective for the company from $540.00 to $730.00 in a report on Tuesday, September 8th. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 28th. Citigroup cut Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a research report on Wednesday, September 9th. Stifel Nicolaus set a $650.00 price objective on Thermo Fisher Scientific in a report on Wednesday, August 5th. Finally, Barclays boosted their target price on Thermo Fisher Scientific from $650.00 to $750.00 and gave the stock an “overweight” rating in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $635.55.

Thermo Fisher Scientific Stock Performance

NYSE TMO traded down $17.20 during trading hours on Thursday, hitting $644.86. The company had a trading volume of 1,385,840 shares, compared to its average volume of 2,247,130. The business has a 50 day moving average of $624.23 and a 200-day moving average of $539.29. The company has a market cap of $238.44 billion, a PE ratio of 34.65, a price-to-earnings-growth ratio of 2.75 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $694.33. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business’s revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.